Thailand's National Science and Technology Development Agency (NSTDA) has unveiled an experimental screening platform for latent tuberculosis that combines nanotechnology, portable scanners, and machine learning—a system designed to deliver test results in under 60 minutes rather than the 1-2 days required by conventional laboratory workflows. The three-day field demonstration ending today in Roi Et and Khon Kaen marks the first real-world trial of SERS-TB, a collaboration between government research institutes, provincial hospitals, and Khon Kaen University aimed at slashing TB incidence in the Northeast by 2035.
Why This Matters
• Speed: Traditional blood tests for latent TB take 1-2 days; SERS-TB aims for less than 60 minutes, potentially as fast as 10 minutes in optimal conditions.
• Reach: Portable Raman spectrometers mean point-of-care screening in remote health centers, cutting the bottleneck at urban hospitals.
• Accuracy: Machine-learning analysis of blood samples achieved 93% accuracy in identifying latent infections during pilot studies in Northeast Thailand.
• Scale: An estimated 16% of Thailand's general population carries dormant TB bacteria; among prisoners and healthcare workers, prevalence exceeds 40%.
How the Technology Works
SERS-TB stands for Surface-Enhanced Raman Spectroscopy-Tuberculosis. A nurse or technician places a single drop of blood onto a nano-structured silver chip that amplifies the molecular signature of tuberculosis proteins. A hand-held Raman spectrometer then scans the chip, transmitting raw spectral data to cloud-based or on-device artificial intelligence software trained to distinguish latent infection from healthy plasma. While initial trial data shows some results appearing in as little as 10 minutes in optimal conditions, the system is designed to deliver results within 60 minutes—dramatically faster than conventional methods.
That stands in sharp contrast to the Interferon-Gamma Release Assay (IGRA) and Tuberculin Skin Test (TST), the current standard for latent TB screening. IGRA blood samples must be incubated overnight and analyzed in a certified lab; TST requires a return clinic visit 48-72 hours after the initial injection. Both methods work reasonably well in urban settings but create logistical headaches for district health offices covering dozens of villages. Because latent TB shows no symptoms—patients feel entirely healthy—many never return for the second appointment, leaving infections undetected until they progress to active, contagious disease.
The Latent TB Challenge
Thailand reported roughly 111,000 active TB cases in 2022, translating to 155 cases per 100,000 population, one of the highest rates in Southeast Asia. The figure captures only symptomatic patients; a far larger reservoir of people harbor dormant Mycobacterium tuberculosis bacteria that can reactivate years later, especially if the immune system weakens due to HIV, diabetes, or aging. Global estimates suggest one in four people worldwide carry latent TB, and Thailand's own surveys place the domestic prevalence at 16% among HIV-negative adults. Among high-risk groups—people living with HIV (20-62%), male prisoners (47%), and healthcare workers (40%)—the burden is substantially higher.
Current National Guidelines on HIV/AIDS Treatment and Prevention (2021/2022) recommend LTBI screening only for HIV-positive individuals and a handful of other priority populations, largely because TST and IGRA reagents are expensive and in limited supply outside Bangkok and major regional centers. SERS-TB's portable form factor and lower reagent cost—silver nano-chips can be mass-produced—could enable district hospitals to screen walk-in patients without waiting weeks for lab capacity or budget allocation from the provincial health office.
Field Demonstration and Next Steps
Over the weekend teams from Nectec, Khon Kaen University, Roi Et Hospital, and the Health Region 7 office enrolled volunteers at two rural clinics, comparing SERS-TB results against simultaneous IGRA blood draws processed at the provincial reference lab. Preliminary concordance data will inform refinements to the AI algorithm and guide decisions on chip storage conditions in Thailand's humid climate. Researchers acknowledge that adapting the prototype to real hospital workflows—integrating it with electronic medical records, training staff unfamiliar with spectroscopy, and establishing quality-control protocols—remains the immediate hurdle before wider rollout.
The Thailand Ministry of Public Health's Operational Plan to End Tuberculosis, Phase 2 (2023-2027) lists innovation in rapid diagnostics as a strategic priority, earmarking funds for research partnerships that can move laboratory inventions into clinics. SERS-TB is one of several AI-assisted tools vying for adoption; radiology platforms such as Genki AI and RAMAAI are already interpreting chest X-rays for signs of active pulmonary TB in some provincial hospitals. If SERS-TB proves reliable and cost-effective in the current trial, the consortium expects to launch a 12-month multicenter study across Northeast Thailand in early 2027, with commercial production and national rollout targeted for 2028-2029, according to statements by NSTDA officials.
What This Means for Residents
For expats, migrant workers, and long-term residents in Thailand, routine TB screening is typically not required unless you work in healthcare, apply for certain visa categories, or develop symptoms. However, the arrival of rapid, accessible LTBI testing could change that calculus. Employers in high-contact industries—hospitality, education, healthcare—may begin offering voluntary annual screens once point-of-care devices become widely available. Catching latent TB early allows a short course of preventive antibiotics—usually 3-4 months of daily isoniazid or weekly rifapentine—dramatically reducing the lifetime risk of active disease.
Practically, if you live in Isan (Northeast Thailand) and visit a district health center in the next few years, you might encounter a small suitcase-sized Raman spectrometer and be offered a fingerstick test on the spot. Results would appear on a tablet screen before you leave the clinic, and a positive finding would trigger immediate counseling and a prescription, rather than a referral to a distant provincial hospital. For rural communities where transportation costs and lost workdays discourage follow-up appointments, that convenience could translate into thousands of prevented transmissions.
Broader Context: Thailand's AI Health Push
The SERS-TB initiative fits within a broader national pivot toward artificial intelligence in public health. The Thailand 4.0 economic model prioritizes digital transformation and innovation-driven growth, and the healthcare sector has become a proving ground. Beyond tuberculosis, Thai universities and government labs are deploying machine learning for dengue outbreak prediction, automated triage in emergency departments, and personalized cancer treatment planning. The NSTDA has positioned itself as the coordinating agency, channeling research grants, brokering university-hospital partnerships, and negotiating intellectual-property arrangements that keep core technologies under Thai ownership.
Critics point out that high-tech solutions can widen health inequities if deployment favors well-resourced urban hospitals. The SERS-TB team has addressed this concern by designing the system explicitly for point-of-care use in remote areas, with solar-chargeable battery packs, offline AI inference, and a user interface in Thai that requires minimal technical training. Chips are stable at room temperature for several months, eliminating the cold-chain logistics that hamper vaccine and reagent distribution in hot, rural provinces.
Competing Technologies
Thailand is not alone in racing to deploy rapid TB diagnostics. The Xpert MTB/RIF molecular assay, endorsed by the World Health Organization, can detect active TB and rifampicin resistance in two hours, and several Bangkok hospitals already use it as a first-line test. However, Xpert machines are expensive—around ฿1.2M per unit—and cartridges cost roughly ฿350 each, making universal screening financially prohibitive. SERS-TB chips are projected to cost under ฿50 apiece at scale, and a single portable spectrometer (฿600,000) can serve an entire district. More importantly, SERS targets latent infection, which Xpert cannot detect because it relies on bacterial DNA in sputum—something asymptomatic carriers do not produce.
As Thailand pushes toward the 2030 global target to end TB as a public health threat, technologies that identify the hidden reservoir of latent cases will be essential. The SERS-TB demonstration this week offers a glimpse of what that future might look like: fast, affordable, and village-level screening powered by algorithms trained on Thai patient data, addressing a disease burden that has persisted for generations.
